GENMAB A/S

CVRCVR number21023884

Core data

Name	GENMAB A/S
Address	Carl Jacobsens Vej 30, 2500, Valby
Founded	Jun 11, 1998
	676 / 595
Locations (P-units)	2 View locations
Website	https://www.genmab.com/
Facebook	61593899126873
Instagram	@genmab.biotech
LinkedIn	genmab
Branch	Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)

Name	GENMAB A/S
Address	Carl Jacobsens Vej 30, 2500, Valby
Founded	Jun 11, 1998
	676 / 595
Locations (P-units)	2 View locations

Website	https://www.genmab.com/
Facebook	61593899126873
Instagram	@genmab.biotech
LinkedIn	genmab
Branch	Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)

Keep track of GENMAB A/S

Get an email when we detect changes to financial reports, ownership or management. Save yourself checking the company again.

Free account

Description

Genmab is an international biotechnology company focused on innovative and differentiated antibody therapeutics for cancer and other serious diseases.

Genmab develops next-generation therapeutic antibodies and antibody therapies intended to transform the treatment of cancer and other serious diseases.

Products & services

Antibody therapeutics · Next-generation therapeutic antibodies · Antibody discovery and development

Industries

Biotechnology · Antibody therapeutics · Healthcare

Financials

View detailed financials

Reporting period	1 Apr - 30 Jun 202691 days / short periodUSD	1 Jan - 30 Jun 2026Locked181 days / short period	1 Jan - 31 Mar 2026Locked90 days / short period	2025Locked	1 Jul - 30 Sept 2025Locked92 days / short period	1 Jan - 30 Sept 2025Locked273 days / short period	1 Apr - 30 Jun 2025Locked91 days / short period	1 Jan - 30 Jun 2025Locked181 days / short period	1 Jan - 31 Mar 2025Locked90 days / short period	2024Locked	1 Jul - 30 Sept 2024Locked92 days / short period	1 Jan - 30 Sept 2024Locked274 days / short period	1 Apr - 30 Jun 2024Locked91 days / short period	1 Jan - 30 Jun 2024Locked182 days / short period	1 Jan - 31 Mar 2024Locked91 days / short period	2023Locked	1 Jul - 30 Sept 2023Locked92 days / short period	7 Jan - 30 Sept 2023Locked267 days / short period	1 Jan - 30 Sept 2023Locked273 days / short period	1 Apr - 30 Jun 2023Locked91 days / short period	1 Jan - 30 Jun 2023Locked181 days / short period	1 Jan - 31 Mar 2023Locked90 days / short period	1 Jan - 31 Jan 2023Locked31 days / short period	2022Locked	1 Jul - 30 Sept 2022Locked92 days / short period	7 Jan - 30 Sept 2022Locked267 days / short period	1 Jan - 30 Sept 2022Locked273 days / short period	1 Apr - 30 Jun 2022Locked91 days / short period	1 Jan - 30 Jun 2022Locked181 days / short period	1 Jan - 31 Mar 2022Locked90 days / short period	2021Locked	1 Jul - 30 Sept 2021Locked92 days / short period	1 Jan - 30 Sept 2021Locked273 days / short period	1 Apr - 30 Jun 2021Locked91 days / short period	1 Jan - 30 Jun 2021Locked181 days / short period	1 Jan - 31 Mar 2021Locked90 days / short period	2020Locked	1 Jul - 30 Sept 2020Locked92 days / short period	1 Jan - 30 Sept 2020Locked274 days / short period	1 Apr - 30 Jun 2020Locked91 days / short period	1 Jan - 30 Jun 2020Locked182 days / short period	1 Jan - 31 Mar 2020Locked91 days / short period	2019Locked	1 Jul - 30 Sept 2019Locked92 days / short period	1 Jan - 30 Sept 2019Locked273 days / short period	1 Apr - 30 Jun 2019Locked91 days / short period	1 Jan - 30 Jun 2019Locked181 days / short period	1 Jan - 31 Mar 2019Locked90 days / short period	2018Locked	1 Jul - 30 Sept 2018Locked92 days / short period	1 Jan - 30 Sept 2018Locked273 days / short period	1 Apr - 30 Jun 2018Locked91 days / short period	1 Jan - 30 Jun 2018Locked181 days / short period	1 Jan - 31 Mar 2018Locked90 days / short period	2017Locked
Revenue	1,155,000,000	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked
Profit before tax	295,000,000	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked
Net income	303,000,000	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked
Avg. employees	3,108	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked	Locked
2017–2026 Unlock financial history

Datapublica Risk Score

Locked

Assesses the risk of financial distress using the company’s accounts, history, and connections.

Company score

0 · Low100 · High

What goes into the assessment

Financials
Equity ratio, profitability, and liquidity
Accounts and history
Late filings and previous financial distress
Owners and management
Past bankruptcies and owners’ other companies
Company and connections
Age, industry, and shared addresses or contact details

Standard: Score and risk bandPro: Also a detailed explanation of the factors

See plans Learn about Risk Score

Contact

From cvr.dk

Contact	Phone	Email
Company	7020****Show full	in**@genmab.comShow full

From genmab.com

Contact	Phone	Email
Main	—	in**@genmab.comShow full
Company	+86 512 6799 ****Show full	—
United States	+1 609 430 **Show full +1 617 401 **Show full	—
The Netherlands	+31 30 2 12* ***Show full	—
Genmab France SAS	+33 18288****Show full	—
Genmab UK Ltd	+44 204 579 ****Show full	—
LEI Code	+45 7020 ****Show full	—
Genmab Germany GmbH	+49 89 380 3 Show full	—

Gazelle

Loading gazelle status…

Børsen Gazelle is Dagbladet Børsen's award. Datapublica is not affiliated with Børsen. Calculated statuses are Datapublica's own analysis of public CVR financial-statement data.

People

Person	Roles	Titles
Anders Gersel Pedersen	Roles Board	TitlesBESTYRELSESMEDLEM
Martha Theresa Ramirez-Andersen	Roles Board	TitlesSUPPLEANT
Martin Schultz	Roles Board	TitlesBESTYRELSESMEDLEM
Pernille Lyngvold Erenbjerg	Roles Board	TitlesNÆSTFORMAND

Auditor

No auditor data available

Legal owners

View ownership diagram

Owner	Ownership	Voting rights	From
BLACKROCK, INC.🇺🇸 Foreign legal entity	Ownership5–9.99 %	Voting rights5 %	FromJul 18, 2019
Darwin Global Management Limited🇬🇧 Foreign legal entity	Ownership0 %	Voting rights5 %	FromSep 28, 2026

Ultimate owners